Abagovomab

From WikiMD.org
Jump to navigation Jump to search

Abagovomab

Abagovomab (pronunciation: /əˌbæɡoʊˈvoʊmæb/) is a monoclonal antibody designed for the treatment of ovarian cancer. It is an immunotherapy drug that works by stimulating the body's immune system to attack cancer cells.

Etymology

The name "Abagovomab" is derived from the International Nonproprietary Naming system for monoclonal antibodies. The prefix "aba-" is randomly assigned, "govo-" refers to the drug's target (in this case, ovarian cancer), and "-mab" is the suffix for all monoclonal antibodies.

Mechanism of Action

Abagovomab targets a specific protein called CA-125, which is often found in high levels on the surface of ovarian cancer cells. By binding to this protein, abagovomab triggers the immune system to attack and destroy the cancer cells.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
  • Ovarian cancer: A type of cancer that begins in the ovaries.
  • CA-125: A protein that is a so-called tumor marker or biomarker, which is a substance that is found in greater concentration in tumor cells than in other cells of the body.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski